The FDA accepts for review Pfizer's (NYSE:PFE) marketing application seeking approval for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The agency's action is in July.
Tafamidis has Orphan Drug, Fast Track and Breakthrough Therapy status in the U.S. for the indication.
Shares are off a fraction premarket.
Subscribe for full text news in your inbox